Abstract：Objective：To observe the clinical efficacy of the combined use of Prostatitis Formulation Granules and Tamsulosin Hydrochloride Sustained-Release Capsules in the treatment of chronic nonbacterial prostatitis （CNP）. Methods：A retrospective study was conducted on 138 patients with CNP admitted to Pujiang County People's Hospital from May 2021 to May 2024. After excluding 12 cases based on inclusion and exclusion criteria，a total of 126 cases were included as the study subjects. The patients were divided into a control group （62 cases） and a trial group （64 cases） according to the different treatment regimens. The control group was treated with Tamsulosin Hydrochloride Sustained-Release Capsules，while the trial group was treated with Prostatitis Formulation Granules in addition to the treatment of the control group. The clinical efficacy， National Institutes of Health-Chronic Prostatitis Symptom Index （NIH-CPSI） scores， traditional Chinese medicine syndrome scores， prostatic fluid indicators [tumor necrosis factor-α（ TNF-α），interleukin-6（ IL-6），and interleukin-8（ IL-8）］，prostatic exosomal protein（ PSEP）， prostate volume，maximum urine flow rate （MFR），and average urine flow rate （AFR） were compared between the two groups. Results： The total effective rate in the trial group was 92.19% （59/64）， which was higher than that in the control group （77.42%，48/62），with a significant difference （P＜0.05）. After treatment，the scores of each item and the total score of NIH-CPSI in both groups were decreased compared with those before treatment （P＜0.05），and the scores of each item and the total score of NIH-CPSI in the trial group were lower than those in the control group （P＜ 0.05）. After treatment，the total score of traditional Chinese medicine syndrome in both groups was decreased compared with that before treatment （P＜0.05）， and the trial group had a lower score than the control group （P＜0.05）. After treatment， the levels of TNF-α， IL-6， IL-8 in prostatic fluid and PSEP in urine in both groups were decreased compared with those before treatment（ P＜0.05），and the levels of TNF-α，IL-6，IL-8 in prostatic fluid and PSEP in urine in the trial group were lower than those in the control group （P＜0.05）. After treatment，the prostate volume in both groups was decreased compared with that before treatment， and the trial group had a smaller volume than the control group （P＜0.05）；the MFR and AFR in both groups were increased compared with those before treatment，and the trial group had higher values than the control group （P＜0.05）. Conclusion： The combined use of Prostatitis Formulation Granules and Tamsulosin Hydrochloride Sustained-Release Capsules can improve symptoms and urodynamics in patients with CNP， downregulate inflammatory factor levels， reduce prostate volume， and enhance clinical efficacy.